These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39304893)

  • 1. Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer.
    Bourke S; Bennett B; Oluboyede Y; Li T; Longworth L; O'Sullivan SB; Braverman J; Soare IA; Shaw JW
    Health Qual Life Outcomes; 2024 Sep; 22(1):81. PubMed ID: 39304893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
    Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
    Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
    Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
    Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
    Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy.
    Musoro JZ; Sodergren SC; Coens C; Pochesci A; Terada M; King MT; Sprangers MAG; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
    Colorectal Dis; 2020 Dec; 22(12):2278-2287. PubMed ID: 32767619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Dirven L; Musoro JZ; Coens C; Reijneveld JC; Taphoorn MJB; Boele FW; Groenvold M; van den Bent MJ; Stupp R; Velikova G; Cocks K; Sprangers MAG; King MT; Flechtner HH; Bottomley A
    Neuro Oncol; 2021 Aug; 23(8):1327-1336. PubMed ID: 33598685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
    Musoro JZ; Bottomley A; Coens C; Eggermont AM; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Brandberg Y;
    Eur J Cancer; 2018 Nov; 104():169-181. PubMed ID: 30359910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial.
    Kawahara T; Taira N; Shiroiwa T; Hagiwara Y; Fukuda T; Uemura Y; Mukai H
    Qual Life Res; 2022 Jun; 31(6):1829-1836. PubMed ID: 34982354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials.
    Gamper EM; Musoro JZ; Coens C; Stelmes JJ; Falato C; Groenvold M; Velikova G; Cocks K; Flechtner HH; King MT; Bottomley A;
    BMC Cancer; 2021 Oct; 21(1):1083. PubMed ID: 34620124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer.
    Musoro JZ; Coens C; Fiteni F; Katarzyna P; Cardoso F; Russell NS; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Bottomley A;
    JNCI Cancer Spectr; 2019 Sep; 3(3):pkz037. PubMed ID: 32328553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Internal Responsiveness of EQ-5D-5L and EORTC QLQ-C30 in Dutch Breast Cancer Patients during the First Year Post-Surgery: A Longitudinal Cohort Study.
    Vrancken Peeters NJMC; van Til JA; Huberts AS; Siesling S; Husson O; Koppert LB
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.
    Musoro JZ; Coens C; Sprangers MAG; Brandberg Y; Groenvold M; Flechtner HH; Cocks K; Velikova G; Dirven L; Greimel E; Singer S; Pogoda K; Gamper EM; Sodergren SC; Eggermont A; Koller M; Reijneveld JC; Taphoorn MJB; King MT; Bottomley A;
    Eur J Cancer; 2023 Jul; 188():171-182. PubMed ID: 37257278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
    Huang D; Zeng D; Tang Y; Jiang L; Yang Q
    Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study.
    Brusniak K; Feisst M; Sebesteny L; Hartkopf A; Graf J; Engler T; Schneeweiss A; Wallwiener M; Deutsch TM
    JMIR Cancer; 2021 Oct; 7(4):e25776. PubMed ID: 34636732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
    Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
    J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients.
    Perwitasari DA; Purba FD; Candradewi SF; Marwin M; Permata A; Ulfa Faza MB; Septiantoro BP; Kaptein AA
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1125-1130. PubMed ID: 37116132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.
    Koller M; Musoro JZ; Tomaszewski K; Coens C; King MT; Sprangers MAG; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A
    Lung Cancer; 2022 May; 167():65-72. PubMed ID: 35413526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer.
    Musoro JZ; Coens C; Singer S; Tribius S; Oosting SF; Groenvold M; Simon C; Machiels JP; Grégoire V; Velikova G; Cocks K; Sprangers MAG; King MT; Bottomley A;
    Head Neck; 2020 Nov; 42(11):3141-3152. PubMed ID: 32627261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.